Allarity Therapeutics is making strides towards regaining compliance with Nasdaq Listing Rule 5550(a)(2). This is a significant step for the company as it works towards meeting the requirements set by Nasdaq. The move is part of Allarity Therapeutics’ efforts to maintain its listing on the exchange. By taking decisive action, the company is demonstrating its commitment to meeting the standards set by Nasdaq. This development is a positive sign for Allarity Therapeutics as it continues to work towards its goals.